Published in Nephron Physiol on May 10, 2006
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol (2009) 2.81
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
Hyperphosphatemia of chronic kidney disease. Kidney Int (2008) 1.63
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol (2009) 1.14
Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol (2008) 1.03
FGF-23 Levels before and after Renal Transplantation. J Transplant (2009) 0.93
Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol (2012) 0.92
FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol (2012) 0.92
Disorders of phosphate homeostasis and tissue mineralisation. Endocr Dev (2009) 0.88
Clinical Significance of FGF-23 in Patients with CKD. Int J Nephrol (2011) 0.86
The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol (2014) 0.86
Genetic ablation of sfrp4 in mice does not affect serum phosphate homeostasis. Endocrinology (2011) 0.85
Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol (2012) 0.84
Renal Clearance of Mineral Metabolism Biomarkers. J Am Soc Nephrol (2015) 0.82
Insights from genetic disorders of phosphate homeostasis. Semin Nephrol (2013) 0.81
Renal phosphate handling: Physiology. Indian J Endocrinol Metab (2013) 0.80
Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. Clin Exp Nephrol (2007) 0.80
A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation (2016) 0.79
FGF23 and mineral metabolism in the early post-renal transplantation period. Pediatr Nephrol (2013) 0.79
Tumor-Induced Osteomalacia. Transl Endocrinol Metab (2015) 0.79
Mineral and bone disorder after kidney transplantation. World J Transplant (2015) 0.75
FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study. Clin Kidney J (2016) 0.75
Post-renal transplantation hypophosphatemia. Pediatr Nephrol (2009) 0.75
Model-Based Analysis of FGF23 Regulation in Chronic Kidney Disease. Gene Regul Syst Bio (2010) 0.75
Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens (2016) 0.75
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet (2000) 7.41
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med (1974) 4.23
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab (2002) 4.17
Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest (2003) 3.60
The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab (2001) 3.55
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology (2002) 3.00
Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun (2000) 2.90
MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics (2000) 2.75
Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem (2004) 2.72
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun (2004) 2.52
A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab (1984) 2.38
Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis (1998) 2.18
Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem (2002) 2.12
Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem (2002) 2.12
Calciphylaxis in chronic renal failure. J Am Soc Nephrol (1996) 1.95
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis (2004) 1.93
FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun (2001) 1.90
Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res (2002) 1.84
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int (2004) 1.74
The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int (2004) 1.69
Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab (1995) 1.66
Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest (1996) 1.63
Tumor-induced osteomalacia--unveiling a new hormone. N Engl J Med (1994) 1.61
Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem (2000) 1.52
FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab (2004) 1.43
Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest (2003) 1.42
Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl (2002) 1.34
Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis (2004) 1.29
PHEX gene and hypophosphatemia. Kidney Int (2000) 1.29
Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab (2005) 1.26
Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest (1997) 1.23
Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure. Clin Chem (1986) 1.23
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab (2003) 1.22
Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem (2001) 1.20
Direct renal action of a purified parathyroid extract. Endocrinology (1960) 1.08
Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens (2002) 1.05
The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis (1997) 1.03
Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab (2001) 1.00
Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab (2002) 0.94
The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int (2003) 0.93
Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int (1981) 0.92
The molecular background to hypophosphataemic rickets. Arch Dis Child (2000) 0.91
Post-transplant hypophosphatemia. Kidney Int (2001) 0.91
Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int (2001) 0.91
New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens (2002) 0.90
Phosphatonins: a new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens (2002) 0.89
Molecular mechanisms in proximal tubular and small intestinal phosphate reabsorption (plenary lecture). Mol Membr Biol (2001) 0.88
Tubular dysfunction following kidney transplantation. Nephron (1980) 0.87
Effects of 1,25-dihydroxycholecalciferol on phosphate transport in vitamin D-deprived rats. Am J Physiol (1984) 0.86
Is FGF23 the long sought after phosphaturic factor phosphatonin? Nephrol Dial Transplant (2002) 0.84
Disorders of renal tubular phosphate transport. J Am Soc Nephrol (2003) 0.83
Phosphatonin--a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia) Nephrol Dial Transplant (1997) 0.81
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet (2004) 6.85
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Vitamin D. Am J Physiol Renal Physiol (2005) 4.81
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet (2008) 3.90
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int (2010) 2.35
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett (2008) 2.13
Extracellular synthesis of gold nanoparticles by the fungus Fusarium oxysporum. Chembiochem (2002) 1.86
Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet (2008) 1.84
Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res (2002) 1.84
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A (2013) 1.82
Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis (2003) 1.78
Ultrasmall monodisperse NaYF(4):Yb(3+)/Tm(3+) nanocrystals with enhanced near-infrared to near-infrared upconversion photoluminescence. ACS Nano (2010) 1.76
Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol (2007) 1.73
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A (2013) 1.70
Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ Health Perspect (2007) 1.69
The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int (2004) 1.69
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol (2005) 1.66
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood (2009) 1.64
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst (2005) 1.57
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res (2012) 1.55
Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A (2007) 1.50
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis (2005) 1.48
The utility of computed tomography as a screening tool for the evaluation of pediatric blunt chest trauma. J Trauma (2009) 1.48
The effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty. Cornea (2005) 1.47
Thrombopoietin promotes NHEJ DNA repair in hematopoietic stem cells through specific activation of Erk and NF-κB pathways and their target, IEX-1. Blood (2013) 1.47
Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. Arch Dermatol (2007) 1.47
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood (2013) 1.45
IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44
Voluntary medical male circumcision: a cross-sectional study comparing circumcision self-report and physical examination findings in Lesotho. PLoS One (2011) 1.44
Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res (2009) 1.43
Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest (2003) 1.42
Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol (2009) 1.39
Bioreduction of AuCl(4)(-) Ions by the Fungus, Verticillium sp. and Surface Trapping of the Gold Nanoparticles Formed D.M. and S.S. thank the Council of Scientific and Industrial Research (CSIR), Government of India, for financial assistance. Angew Chem Int Ed Engl (2001) 1.39
Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr (2003) 1.38
Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest (2008) 1.38
A statewide intervention reduces BMI in adults: Shape Up Rhode Island results. Obesity (Silver Spring) (2009) 1.37
Improving weight loss outcomes of community interventions by incorporating behavioral strategies. Am J Public Health (2010) 1.36
Teammates and social influence affect weight loss outcomes in a team-based weight loss competition. Obesity (Silver Spring) (2012) 1.36
Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res (2007) 1.36
Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol (2007) 1.35
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 1.33
Genetics of pigmentation in skin cancer--a review. Mutat Res (2010) 1.33
Effects of 1alpha,25(OH)2D3 and its analogs on dendritic cell function. J Cell Biochem (2003) 1.32
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda) (2009) 1.29
Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis (2004) 1.28
Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A (2009) 1.27
Enzyme mediated extracellular synthesis of CdS nanoparticles by the fungus, Fusarium oxysporum. J Am Chem Soc (2002) 1.26
Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev (2002) 1.26
Arsenic exposure in Hungary, Romania and Slovakia. J Environ Monit (2005) 1.26
Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab (2012) 1.23
Targeted radiotherapy with gold nanoparticles: current status and future perspectives. Nanomedicine (Lond) (2014) 1.22
Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 1.20
Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis (2006) 1.19
Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J Biol Chem (2003) 1.19
Biological activities of pyrazoline derivatives--a recent development. Recent Pat Antiinfect Drug Discov (2009) 1.18
In vivo targeted cancer imaging, sentinel lymph node mapping and multi-channel imaging with biocompatible silicon nanocrystals. ACS Nano (2010) 1.18
Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol (2010) 1.16
Differential regulation of voltage-gated K+ channels by oxidized and reduced pyridine nucleotide coenzymes. Am J Physiol Cell Physiol (2004) 1.16
Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res (2003) 1.16
Update of PAX2 mutations in renal coloboma syndrome and establishment of a locus-specific database. Hum Mutat (2012) 1.15
Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer (2006) 1.14
The structure of the human centrin 2-xeroderma pigmentosum group C protein complex. J Biol Chem (2006) 1.14
The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol (2007) 1.14
Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J Endocrinol (2010) 1.13
Acute myocardial infarction due to blunt chest trauma. Indian Heart J (2003) 1.13
Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol (2008) 1.13
MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res (2009) 1.12
PAX genes in development and disease: the role of PAX2 in urogenital tract development. Int J Dev Biol (2002) 1.12
Malignant peripheral nerve sheath tumors: clinicopathological profile of 63 cases diagnosed at a tertiary cancer referral center in Mumbai, India. Indian J Pathol Microbiol (2010) 1.12
Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis (2011) 1.11
Inorganic arsenic and basal cell carcinoma in areas of Hungary, Romania, and Slovakia: a case-control study. Environ Health Perspect (2012) 1.11
Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population--a candidate gene approach. Int J Cancer (2009) 1.11
Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis (2006) 1.11
Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol (2002) 1.11
Elevated blood pressure and cardiac hypertrophy after ablation of the gly96/IEX-1 gene. J Appl Physiol (1985) (2005) 1.11
Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol (2004) 1.10
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
"Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol (2005) 1.10
Structure, binding interface and hydrophobic transitions of Ca2+-loaded calbindin-D(28K). Nat Struct Mol Biol (2006) 1.09
In vitro radiosensitization by gold nanoparticles during continuous low-dose-rate gamma irradiation with I-125 brachytherapy seeds. Nanomedicine (2012) 1.08